Calistoga Kicks Off Its First Oncology Clinical Trial
Calistoga Pharmaceuticals is beginning a Phase I clinical trial of its lead compound, CAL-101, in patients with hematologic cancer.
The open-label study is the company’s first clinical trial for oncology. It will explore the safety and clinical activity of the drug in patients with chronic lymphocytic leukemia, selected B-cell non-Hodgkin lymphoma and acute myeloid leukemia.
The drug is a small molecule phosphoinositide-3 kinase (PI3K) delta inhibitor. In preclinical trials, it has demonstrated potential to kill primary cancer cells, according to the company.